pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lantus
drug · protein
save

insulin glargine LA

pre_registrationupdated 3mo ago
by Gan & Lee Pharmaceuticals Co Ltd🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval24 co-mentions · 12 sources
  • drugSOLIQUA 100/3324 co-mentions · 12 sources
  • company$SNYSanofi12 co-mentions · 12 sources
  • company$SNYNFSanofi12 co-mentions · 12 sources
  • companySanofi-Aventis US LLC12 co-mentions · 12 sources
  • druginsulin glargine12 co-mentions · 12 sources
  • drugToujeo LA12 co-mentions · 12 sources
  • drug(insulin glargine + lixisenatide)12 co-mentions · 12 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

targets

Insulin receptor

all catalysts(0)

nothing on the calendar yet

Trials studying insulin glargine LA

  • phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellituscompletedn=105
  • phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Beforecompletedn=1,085
  • phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetesrecruitingn=877
  • phase3A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)completedn=485
  • phase3A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Riskcompletedn=2,749
  • phase3A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetescompletedn=429
  • phase4iGlarLixi CGM Study in Chinese T2D Individuals After OADsrecruitingn=678
  • phase3A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetescompletedn=401
more trials →

News(5)

  • STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
    Lilly was accused of charging “grossly” excessive prices for different insulin products that forced some patients to ration or forgo the drug.
    stat · 9d ago
  • Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
    Sanofi is going to "look very deeply" at its late-stage pipeline as part of a portfolio prioritization initiative, though new CEO Belén Garijo didn’t commit to shelving a specific number of assets.
    biospace · 12d ago
  • STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
    In a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugs
    stat · 18d ago
  • A new, separate outbreak of the diarrhea-causing parasite
    A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
    stat · 18d ago
  • STAT+: Popular insulin product enters shortage as other pens leave market
    The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
    stat · 19d ago
brand
Lantus
trade names
Abasaglar, Abasaglar (previously abasria), Abasaglar kwikpen, Basaglar, Ins lantus, Ins lantus opticlik
generic
insulin glargine
MOA
Insulin receptor agonist
indication
Type 1 Diabetes (Juvenile Diabetes)
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?